The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing's sarcoma

被引：0
|
作者：
Dowless, Michele [1 ]
Lowery, Caitlin [1 ]
Renschler, Matthew [1 ]
Blosser, Wayne [1 ]
Stephens, Jennifer [1 ]
Flack, Robert [1 ]
Credille, Kelly [1 ]
Chen, Mia [1 ]
Dorsey, Frank [1 ]
Sams, Lillian [1 ]
Ebert, Philip [1 ]
Olsen, Jonathan [1 ]
Shackleford, Terry [2 ]
Houghton, Peter [2 ]
Stancato, Louis [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] UT Hlth Sci Ctr, Greehey Childrens Canc Res Inst, San Antonio, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 19期
关键词：
D O I：
10.1158/1538-7445.PEDCA17-B43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B43
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib
    Gong Xueqian
    Chio, Li-Chun
    Webster, Yue
    Lallena, Maria Jose
    Boehnke, Karsten
    Torres, Raquel
    Iversen, Phil
    De Dios, Alfonso
    Smith, Ian
    Reinhard, Christoph
    Peng, Sheng-Bin
    Dempsey, Jack
    Burke, Teresa
    Chen, Shih-Hsun
    Stewart, Trent
    Beckmann, Richard
    Wu, Wenjuan
    Buchanan, Sean G.
    MOLECULAR CANCER RESEARCH, 2016, 14
  • [2] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    CANCER RESEARCH, 2020, 80 (16)
  • [3] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [4] A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
    Guenther, Lillian M.
    Dharia, Neekesh V.
    Ross, Linda
    Conway, Amy
    Robichaud, Amanda L.
    Catlett, Jerrel L., II
    Wechsler, Caroline S.
    Frank, Elizabeth S.
    Goodale, Amy
    Church, Alanna J.
    Tseng, Yuen-Yi
    Guha, Rajarshi
    McKnight, Crystal G.
    Janeway, Katherine A.
    Boehm, Jesse S.
    Mora, Jaume
    Davis, Mindy I.
    Alexe, Gabriela
    Piccioni, Federica
    Stegmaier, Kimberly
    CLINICAL CANCER RESEARCH, 2019, 25 (04) : 1343 - 1357
  • [5] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [6] Abemaciclib (CDK4/6 Inhibitor) Blockade Induces Cytotoxicity in Human Anaplastic Thyroid Carcinoma Cells
    Abutorabi, Elaheh Seyed
    Irani, Shiva
    Yaghmaie, Marjan
    Ghaffari, Seyed Hamid
    REPORTS OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2020, 8 (04): : 438 - 445
  • [7] Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib (LEE011) compared with that of palbociclib and abemaciclib
    Tiedt, Ralph
    Delach, Scott
    Kovats, Steven
    Horn, Thomas
    Acker, Michael
    Engstler, Barbara Schacher
    Caponigro, Giordano
    Su, Fei
    CANCER RESEARCH, 2017, 77
  • [8] Lysosome-targeted cytocidal effect of CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2018, 109 : 1026 - 1026
  • [9] Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
    Liang, Muh-Lii
    Chen, Chun-Han
    Liu, Yun-Ru
    Huang, Man-Hsu
    Lin, Yu-Chen
    Wong, Tai-Tong
    Lin, Sey-En
    Chu, Shing-Shiung
    Ding, Yi-Huei
    Hsieh, Tsung-Han
    CANCERS, 2020, 12 (12) : 1 - 17
  • [10] A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib
    Chong, Qing-Yun
    Kok, Ze-Hui
    Bui, Ngoc-Linh-Chi
    Xiang, Xiaoqiang
    Wong, Andrea Li-Ann
    Yong, Wei-Peng
    Sethi, Gautam
    Lobie, Peter E.
    Wang, Lingzhi
    Goh, Boon-Cher
    PHARMACOLOGICAL RESEARCH, 2020, 156
12345